7 research outputs found
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Purpose
To perform a critical analysis on the impact of depth of response in newly diagnosed multiple
myeloma (MM).
Patients and Methods
Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma)
2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical
trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months
after study enrollment. Median follow-up of the series was 71 months.
Results
Achievement of complete remission (CR) in the absence of MRD negativity was not associated with
prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial
response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months,
respectively). MRD-negative status was strongly associated with prolonged PFS (median,
63 months; P , .001) and OS (median not reached; P , .001) overall and in subgroups defined by
prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity
versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics
showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to
CR) for response assessment. Superior MRD-negative rates after different induction regimens
anticipated prolonged PFS. Among 34 MRD-negative patients withMMand a phenotypic pattern of
bone marrow involvement similar to monoclonal gammopathy of undetermined significance at
diagnosis, the probability of “operational cure” was high; median PFS was 12 years, and the 10-year
OS rate was 94%.
Conclusion
Our results demonstrate that MRD-negative status surpasses the prognostic value of CR
achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or
patient risk group. MRD negativity should be considered as one of the most relevant end points for
transplant-eligible and elderly fit patients with MM
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1,265 patients enrolled in four consecutive clinical trials
Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19pos, CD27neg, CD38lo, CD45pos, CD81pos, CD117neg and CD138lo expression predicted inferior outcomes. Through principal component analysis, we found that simultaneous CD38lowCD81posCD117neg expression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients
Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma
The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible than elderly patients. Since an optimal balance between treatment efficacy and toxicity is of utmost importance in elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used 2nd generation 8-color multiparameter-flow-cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study, The transition from 1st to 2nd generation MFC resulted in increased sensitivity, and allowed to identify three patient groups according to MRD levels: MRD-negative (75-years (HR:4.8; P<.001), and those with high-risk cytogenetics (HR:12.6; P=.01). Using 2nd generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate and favorable outcome (25%, 61% and 100% OS at 3-years; P=.01); the later patients being characterized by an increased compartment of mature B-cells. Our results show that similarly to transplant-candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM, irrespectively of patients’ age and cytogenetic risk
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
Purpose: The ENEST1st sub-analysis presents data based on Philadelphia chromosome (Ph) status, i.e., Ph+ and Phâ\u88\u92/BCR-ABL1 + chronic myeloid leukemia. Methods: Patients received nilotinib 300Â mg twice daily, up to 24 months. Results: At screening, 983 patients were identified as Ph+ and 30 patients as Phâ\u88\u92/BCR-ABL + based on cytogenetic and RT-PCR assessment; 76 patients had unknown karyotype (excluded from this sub-analysis). In the Phâ\u88\u92/BCR-ABL1 + subgroup, no additional chromosomal aberrations were reported. In the Ph+ subgroup, 952 patients had safety and molecular assessments. In the Phâ\u88\u92/BCR-ABL1 + subgroup, 30 patients had safety assessments and 28 were followed up for molecular assessments. At 18 months, the molecular response (MR) 4 rate [MR4; BCR-ABL1 â\u89¤0.01% on International Scale (IS)] was similar in the Phâ\u88\u92/BCR-ABL1+ (39.3%) and Ph+ subgroups (38.1%). By 24 months, the cumulative rates of major molecular response (BCR-ABL1ISâ\u89¤0.1%;), MR4, and MR4.5(BCR-ABL1ISâ\u89¤0.0032%) were 85.7, 60.7, and 50.0%, respectively, in the Phâ\u88\u92/BCR-ABL1 + subgroup, and 80.3, 54.7, and 38.3%, respectively, in the Ph+ subgroup. In both Phâ\u88\u92/BCR-ABL1 + and Ph+ subgroups, rash (20 and 22%), pruritus (16.7 and 16.7%), nasopharyngitis (13.3 and 10.4%), fatigue (10 and 14.2%), headache (10 and 15.8%), and nausea (6.7 vs 11.4%) were frequent non-hematologic adverse events, whereas hypophosphatemia (23.3 and 6.8%), anemia (10 and 6.5%), and thrombocytopenia (3.3 and 10.2%) were the common hematologic/biochemical laboratory events. Conclusion: Based on similar molecular response and safety results in both subgroups, we conclude that Phâ\u88\u92/BCR-ABL1 + patients benefit from nilotinib in the same way as Ph+ patients
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Purpose
To perform a critical analysis on the impact of depth of response in newly diagnosed multiple
myeloma (MM).
Patients and Methods
Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma)
2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical
trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months
after study enrollment. Median follow-up of the series was 71 months.
Results
Achievement of complete remission (CR) in the absence of MRD negativity was not associated with
prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial
response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months,
respectively). MRD-negative status was strongly associated with prolonged PFS (median,
63 months; P , .001) and OS (median not reached; P , .001) overall and in subgroups defined by
prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity
versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics
showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to
CR) for response assessment. Superior MRD-negative rates after different induction regimens
anticipated prolonged PFS. Among 34 MRD-negative patients withMMand a phenotypic pattern of
bone marrow involvement similar to monoclonal gammopathy of undetermined significance at
diagnosis, the probability of “operational cure” was high; median PFS was 12 years, and the 10-year
OS rate was 94%.
Conclusion
Our results demonstrate that MRD-negative status surpasses the prognostic value of CR
achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or
patient risk group. MRD negativity should be considered as one of the most relevant end points for
transplant-eligible and elderly fit patients with MM
Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma
The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible than elderly patients. Since an optimal balance between treatment efficacy and toxicity is of utmost importance in elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used 2nd generation 8-color multiparameter-flow-cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study, The transition from 1st to 2nd generation MFC resulted in increased sensitivity, and allowed to identify three patient groups according to MRD levels: MRD-negative (75-years (HR:4.8; P<.001), and those with high-risk cytogenetics (HR:12.6; P=.01). Using 2nd generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate and favorable outcome (25%, 61% and 100% OS at 3-years; P=.01); the later patients being characterized by an increased compartment of mature B-cells. Our results show that similarly to transplant-candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM, irrespectively of patients’ age and cytogenetic risk